CA2412861A1 - Process and intermediates for production of cabergoline and related compounds - Google Patents
Process and intermediates for production of cabergoline and related compounds Download PDFInfo
- Publication number
- CA2412861A1 CA2412861A1 CA002412861A CA2412861A CA2412861A1 CA 2412861 A1 CA2412861 A1 CA 2412861A1 CA 002412861 A CA002412861 A CA 002412861A CA 2412861 A CA2412861 A CA 2412861A CA 2412861 A1 CA2412861 A1 CA 2412861A1
- Authority
- CA
- Canada
- Prior art keywords
- process according
- trimethylsilyl
- compound
- formula
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
Abstract
A process for preparation of <i>N</i>-(ergoline-8.beta.-carbonyl)ureas of the formula [I] their stereoisomers as well as acid addition salts thereof which process comprises silylating an ergoline -8.beta.-carboxamide of the formula [2], their stereoisomers as well as metal or ammonium salts or acid addition salts thereof and reacting the resultant product with an isocyanates R1N=C=O
[5] wherein R1 is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl , R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; followed by desilylation. This novel approach provides an efficient method for preparation of <i>N</i>-(ergoline-8.beta.-carbonyl)ureas of the formula [I] which can be useful as anty-Parkinson drugs and prolactin inhibitors. One of the most potent antiprolactinic agent of the class of compounds prepared according to the present invention is Cabergoline. Silylated ergolines, which are obtained as intermediates in the process of the present invention, are novel compounds and represent a further aspect of the invention.
[5] wherein R1 is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl , R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; followed by desilylation. This novel approach provides an efficient method for preparation of <i>N</i>-(ergoline-8.beta.-carbonyl)ureas of the formula [I] which can be useful as anty-Parkinson drugs and prolactin inhibitors. One of the most potent antiprolactinic agent of the class of compounds prepared according to the present invention is Cabergoline. Silylated ergolines, which are obtained as intermediates in the process of the present invention, are novel compounds and represent a further aspect of the invention.
Description
Process and Intermediates for Production of Cabergoline and Related Compounds FIELD OF THE INVENTION
This invention relates to a new process for the preparation of dopamine agonists such as Cabergoline, to some novel intermediates used in this process and to their preparation.
BACKGROUND OF THE INVENTION
N-(Ergoline-8~3-carbonyl)ureas of formula [I]
I H
O N~N~Rl ~'O
Hi.. N.R3 H
N
H ~R4 [I]
1o wherein RI represents an alkyl group having from 1 to 4 carbon atoms, a cyclohexyl group or a phenyl group or a dimethylamino alkyl group -(CH2)"NMe2 in which n is an integer , R2 represents any of the groups which RI may represent, or a hydrogen atom or a pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl residue, R3 represents a hydrocarbon group having from 1 to 4 Is carbon atoms, R4 represents a hydrogen or a halogen atom or a methylthio or phenylthio group and RS represents a hydrogen atom or a methyl group; have shown potent dopamine agonist properties and have been useful as anti-Parl~inson drugs and as prolactin inhibitors (US 5,382,669 and Eur. J. Med. Chem., 1989, v.
24, 421).
One of the most potent prolactin inhibitor of this class is 1-(6-allylergoline-8 [i-carbonyl)- I - [3 -(dimethylamino)propyl]-3 -ethylurea (international non-proprietary name Cabergoline) [la] (Eur. J. Med. Chem., 1989, v. 24, 421) which was firstly prepared by reaction of 6-allylergoline-8~i-carboxylic acid [7] with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (US 4,526,892) (Scheme 1):
to H
N
~H
HN-J ~
EtN=C=N(CH~3NMe~
H~
EtHN~O Me~N~N~O
O ]N'~NMe~ O ]N'Et H,~, I H,~ i ~ H~ I ~ H
i i HN , HN
Cabergoline ( 1a ] By-product [ 8 Scheme 1 In this case both regioisomers [la] and [8] were obtained and the yield of the isolated Cabergoline [la] is low as a consequence of isolation difficulties.
Another method for Cabergoline preparation (Eur. J. Med. Chem., 1989, v.
This invention relates to a new process for the preparation of dopamine agonists such as Cabergoline, to some novel intermediates used in this process and to their preparation.
BACKGROUND OF THE INVENTION
N-(Ergoline-8~3-carbonyl)ureas of formula [I]
I H
O N~N~Rl ~'O
Hi.. N.R3 H
N
H ~R4 [I]
1o wherein RI represents an alkyl group having from 1 to 4 carbon atoms, a cyclohexyl group or a phenyl group or a dimethylamino alkyl group -(CH2)"NMe2 in which n is an integer , R2 represents any of the groups which RI may represent, or a hydrogen atom or a pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl residue, R3 represents a hydrocarbon group having from 1 to 4 Is carbon atoms, R4 represents a hydrogen or a halogen atom or a methylthio or phenylthio group and RS represents a hydrogen atom or a methyl group; have shown potent dopamine agonist properties and have been useful as anti-Parl~inson drugs and as prolactin inhibitors (US 5,382,669 and Eur. J. Med. Chem., 1989, v.
24, 421).
One of the most potent prolactin inhibitor of this class is 1-(6-allylergoline-8 [i-carbonyl)- I - [3 -(dimethylamino)propyl]-3 -ethylurea (international non-proprietary name Cabergoline) [la] (Eur. J. Med. Chem., 1989, v. 24, 421) which was firstly prepared by reaction of 6-allylergoline-8~i-carboxylic acid [7] with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (US 4,526,892) (Scheme 1):
to H
N
~H
HN-J ~
EtN=C=N(CH~3NMe~
H~
EtHN~O Me~N~N~O
O ]N'~NMe~ O ]N'Et H,~, I H,~ i ~ H~ I ~ H
i i HN , HN
Cabergoline ( 1a ] By-product [ 8 Scheme 1 In this case both regioisomers [la] and [8] were obtained and the yield of the isolated Cabergoline [la] is low as a consequence of isolation difficulties.
Another method for Cabergoline preparation (Eur. J. Med. Chem., 1989, v.
24, 421 and BP 2,103,603) was based on the direct reaction of N [3-(dimethylamino)propyl]-6-allylergoline-8[i-carboxamide [2a] with ethyl isocyanate (Scheme 2):
EtHN ~O
~'H
N~NMe~ f ~NMe2 EtNCo H
[2a] a]
Scheme 2 to However, this approach required large amounts of ethyl isocyanate (up to 40 eq.) and reflux in toluene for several days. The use of large quantities of toxic isocyanate under drastic reaction conditions represented the major limitation for the large-scale preparation of Cabergoline by this route.
The method proposed in LTS 5,382,669 and Syn. Lett., 1995, 605 is based is on copper salts catalyzed reaction of ethyl isocyanate with carboxamide [2a]
using phosphorous ligands. Drawbacks of this approach are the use of heavy metal ions on the final step of the synthesis and decreasing chemoselectivity with increasing conversion of this reaction.
EtHN ~O
~'H
N~NMe~ f ~NMe2 EtNCo H
[2a] a]
Scheme 2 to However, this approach required large amounts of ethyl isocyanate (up to 40 eq.) and reflux in toluene for several days. The use of large quantities of toxic isocyanate under drastic reaction conditions represented the major limitation for the large-scale preparation of Cabergoline by this route.
The method proposed in LTS 5,382,669 and Syn. Lett., 1995, 605 is based is on copper salts catalyzed reaction of ethyl isocyanate with carboxamide [2a]
using phosphorous ligands. Drawbacks of this approach are the use of heavy metal ions on the final step of the synthesis and decreasing chemoselectivity with increasing conversion of this reaction.
SUMMARY OF THE INVENTION
All the previously disclosed methods for the preparation of Cabergoline present serious drawbacks for producing material suitable for use as a pharmaceutical drug. A desirable goal, met by the present invention, has been to s devise a new synthetic method, which avoids use of heavy metal salts, and which cleanly produces the desired Cabergoline [la] under mild reaction conditions, avoiding tedious and expensive purification steps.
The present invention provides a commercially acceptable process for producingN-(ergoline-8~3-carbonyl)ureas of formula [I]:
Rz I H
O N~N~Ri ~O
H,, . I
N~Rs H
N
H Rø II1 including their stereoisomers as well as acid addition salts thereof, wherein Rl is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, is phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl , R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and 2o R4 is selected from hydrogen, halogen, methylthio and phenylthio group;
which process comprises silylating an ergoline-8-carboxamide of formula [2], -S-H
~Ra ~R3 [~]
including stereoisomers as well as metal or ammonium salts or acid addition salts thereof, wherein Rl, RZ, R3 and R4 are as defined above, reacting the obtained product with isocyanate of the formula [5]
Rl N=C=O
All the previously disclosed methods for the preparation of Cabergoline present serious drawbacks for producing material suitable for use as a pharmaceutical drug. A desirable goal, met by the present invention, has been to s devise a new synthetic method, which avoids use of heavy metal salts, and which cleanly produces the desired Cabergoline [la] under mild reaction conditions, avoiding tedious and expensive purification steps.
The present invention provides a commercially acceptable process for producingN-(ergoline-8~3-carbonyl)ureas of formula [I]:
Rz I H
O N~N~Ri ~O
H,, . I
N~Rs H
N
H Rø II1 including their stereoisomers as well as acid addition salts thereof, wherein Rl is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, is phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl , R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and 2o R4 is selected from hydrogen, halogen, methylthio and phenylthio group;
which process comprises silylating an ergoline-8-carboxamide of formula [2], -S-H
~Ra ~R3 [~]
including stereoisomers as well as metal or ammonium salts or acid addition salts thereof, wherein Rl, RZ, R3 and R4 are as defined above, reacting the obtained product with isocyanate of the formula [5]
Rl N=C=O
[5]
followed by desilylation.
This novel approach was used for the preparation of the known 1o antiprolactinic and anti-Parkinson agent Cabergoline [la] and related compounds.
O \ /NHEt n ~r\~NMe2 [ la Other features and advantages will be apparent from the specification and claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention describes a novel process for the preparation of N (ergoline-8(3-carbonyl)urea compounds of formula [I]. Particularly, the present invention utilizes the silylation of of ergoline-8~i-carboxamide [2] in order to selectively activate it's amide group in the subsequent reaction with isocyanate.
to This novel approach has the following advantages:
~ Silylated ergoline-8[i-carboxamides react with isocyanates to give, after desilylation of intermediates, the desired N (ergoline-8 [i-carbonyl)ureas [I]
with high yield and purity.
~ Reagents used for silylation and desilylation are not toxic, conunercially is available and inexpensive.
Although any silylating agents, suitable for silylating amides, can be used for silylating ergoline-8~i-carboxamide [2], a compound of formula [3] is preferably used for this purpose to give intermediate N silylamide of the formula [4], tautomers or mixtures thereof, stereoisomers, as well as addition salts 2o thereof; intermediate [4] reacts with isocyanate of formula [5]
R
.SI~R~
R6 ~ R3 i Y-Si RR Rl N=C=O
[3] [4] [5]
followed by desilylation.
This novel approach was used for the preparation of the known 1o antiprolactinic and anti-Parkinson agent Cabergoline [la] and related compounds.
O \ /NHEt n ~r\~NMe2 [ la Other features and advantages will be apparent from the specification and claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention describes a novel process for the preparation of N (ergoline-8(3-carbonyl)urea compounds of formula [I]. Particularly, the present invention utilizes the silylation of of ergoline-8~i-carboxamide [2] in order to selectively activate it's amide group in the subsequent reaction with isocyanate.
to This novel approach has the following advantages:
~ Silylated ergoline-8[i-carboxamides react with isocyanates to give, after desilylation of intermediates, the desired N (ergoline-8 [i-carbonyl)ureas [I]
with high yield and purity.
~ Reagents used for silylation and desilylation are not toxic, conunercially is available and inexpensive.
Although any silylating agents, suitable for silylating amides, can be used for silylating ergoline-8~i-carboxamide [2], a compound of formula [3] is preferably used for this purpose to give intermediate N silylamide of the formula [4], tautomers or mixtures thereof, stereoisomers, as well as addition salts 2o thereof; intermediate [4] reacts with isocyanate of formula [5]
R
.SI~R~
R6 ~ R3 i Y-Si RR Rl N=C=O
[3] [4] [5]
wherein R6, R' and R8 may be the same or different and are selected from the group consisting of all~yl having from 1 to 6 carbon atoms, aryl and aralkyl radicals;
s Y is selected from the group consisting of chloro, bromo, iodo, (haloalkyl)-sulfonyloxy, all~ylsulfonyloxy, arylsulfonyloxy, (trialkylsilyloxy)sulfonyloxy, imidazolyl, N acyl-N-alkylamino, N acyl-N (trialkylsilyl)amino, (trialkylsilyl)-amino, N,N dialkylamino, isopropenyloxy, 1-alkoxy-1-alkenyloxy and trichloroacetoxy radicals;
1o and R2, R3 and R4 are as defined above, to give O-silylated N [ergoline-8~i-carbonyl]urea represented by formula [6]:
,R
~~.SI ~R~
N.RI R8 [6]
is including , tautomers or mixtures thereof, stereoisomers, as well as addition salts thereof, wherein Rl, R~, R3, R4, R6, R~ and Rg are as defined above; following desilylation of the above compounds) to obtain the desired N (ergoline-8~i-carbonyl)urea [I], which can be converted into acid addition salts thereof.
2o The silylating agent may be used in a 0.5 to 10 fold molar amount, preferably from 0.9 to 5 fold molar amount, relative to the amount of the ergoline-8~i-carboxamide [2]. Preferably, silylating agents are selected from -g_ trimethylsilyl trifluoromethanesulfonate, trimethylsilyl methanesulfonate, trimethylsilyl benzenesulfonate, trimethylsilyl chlorosulfonate, trimethylsilyl chloride, bromide or iodide, trimethylsilyl trichloroacetate and trifluoroacetate, 1-(trimethylsilyl)imidazol, I-(trimethylsilyl)-1,2,4-triazole, 1-(trimethylsilyl)-1H-benzotriazole, 1-(trimethylsilyl)-2-pyrrolidinone, N methyl-N (trimethylsilyl)trifluoroacetamide, methyl trimethylsilyl dimethyll~etene acetal, bis(trimethylsilyl)sulfate, N,O-bis(trimethylsilyl)acetamide and bis(trimethylsilyl)trifluoroacetamide.
The silylation reaction may be carried out from -50 °C to the reflux to temperature of the reaction mixture. Preferably, the silylation is carried out from 0° to 50 °C.
Organic or inorganic acids or salts may accelerate the silylation.
Examples of such acids include mineral acids such as sulfuric acid or hydrogen halide. Examples of salts include metal halides, tertiary ammonium halides, is ammonium halides, ammonium sulfate, pyridine or it's derivatives hydrohalides.
However, preferably, organic or inorganic bases accelerate the silylation reaction.
Examples of organic bases are tertiary amines, sterically hindered secondary amines, pyridine or there derivatives, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or mixture thereof. Examples of 2o tertiary amines include I-ethylpiperidine, 1-butylpyrrolidine, diisopropylethylamine, triethylamine, N,N,N,N-tetramethylethylenediamine, 1,4-diazabicyclo[2.2.2]octane or mixture thereof. Examples of sterically hindered secondary amines are diisopropylamine, dicyclohexylamine, 2,2,6,6-tetramethylpiperidine or mixture thereof. Examples of pyridine 25 derivatives axe 4-dimethylaminopyridine (DMAP), 4-(4-methylpiperidino)pyridine and 4-pyrrolidinopyridine or mixture thereof.
The solvent for the silylation reaction may be any suitable aprotic organic solvent provided it does not inhibit the reaction. Examples thereof include aromatic hydrocarbons such as benzene, toluene and xylene, chlorobenzene, 30 o-dichlorobenzene, m-dichlorobenzene and bromobenzene; hydrocarbon halides such as dichloromethane and chloroform; ether solvents such as ether, isopropyl ether, tent-butyl methyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, tetrahydrofuran (THF); ester-type solvents such as ethyl acetate, isopropyl acetate, butyl acetate; or highly polar aprotic organic solvents such as acetonitrile, s N,N dimethylformamide (DMF), N,N dimethylacetamide or 1-methylpyrrolidinone (NMP).
The resultant silylated product may be used in the following step after isolation from the reaction mass, or may be subjected to the subsequent step without isolation.
1o After silylation, the resultant product is reacted with a compound of formula [5], which may be used in a 1 to 10 fold molar amount, preferably 2 to fold molar amount relative to the amount of the ergoline-8~i-carboxamide [2].
The reaction may be carried out at temperature from -50 °C to reflux temperature of the reaction mixture. Preferably, the reaction is carried out at 0 - 50 °C without is isolating silylated ergoline-8(3-carboxamide from the reaction mass.
The reaction of silylated ergoline-8(3-carboxamide with isocyanate may be carried out without solvent, but preferably, the reaction is carried out in any organic aprotic solvent which does not inhibit the reaction. Examples thereof include aromatic hydrocarbons such as benzene, toluene and xylene, 2o chlorobenzene, o-dichlorobenzene, m-dichlorobenzene and bromobenzene;
hydrocarbon halides such as dichloromethane and chloroform; ether solvents such as ether, isopropyl ether, tent-butyl methyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, tetrahydrofuran (THF); ester-type solvents such as ethyl acetate, isopropyl acetate, butyl acetate; or highly polar aprotic organic solvents 2s such as acetonitrile, N,N dimethylformamide (DMF), N,N dimethylacetamide or 1-methylpyrrolidinone (NMP).
Optionally, the reaction of silylated ergoline-8(3-carboxamide with isocyanate may be accelerated by transition metals) salts) and/or coordination compounds) or fluoride-ions. Examples of the said transition metals include 3o copper or zinc. Preferably, the said transition metals) salts) are copper and/or zinc halides. Preferably the said ligands in the coordination compounds) with transition metals) contain phosphorous, nitrogen and/or oxygen atoms. Examples of the ligands include triarylphosphines, pyridine or it's derivatives, tertiary amines, nitrites, amides and ether-type compounds.
The desilylation can be carried out by, for example, using fluoride salts optionally in the presence of phase transfer catalysts. Examples of the said fluoride salts include tetraalkylammonium fluoride, benzyltrialkylammonium fluoride and alkali metal fluoride. Examples of the said phase transfer catalysts include tetraalkylammonium salts, benzyltrialkylammonium salts and crown to ethers.
Cabergoline [la] may be prepared from amide [2a] according to Scheme 3:
R6 Rs_Si -R~
~, NMe2 Y_Si R~ n ~y/'~, NMe2 i8 R
[3]
[2a] [4a]
~, EtNCO
R~
O NHEt RS Si0 NEt n ~.T~NMe2 n rr~NMe2 Desilylation [ 6a ]
Cabergoline ( la ]
Scheme 3 The invention will be further described in more detail with the following non-limiting examples.
Example 1 Cabergoline [Ia]
O \ / NHEt ~'H
~ NMe2 ~ NMe2 1. TMSOTf/Et3N
EtN=C=O
2. Desilylation [ ~a ] ~u~
Cabergoline [ Ia ]
to Scheme 4 Typical procedure A.
A tree-necked round-bottom flask fitted with a reflux condenser (optional), thermometer and septum was evacuated, dried and flushed with dry nitrogen or argon. Solution of amide [2a] (3.00 g, 7.9 mmol) and triethylamine s (1.11 g, 11.0 mmol) in dichloromethane (30 mL) was cooled to 0 =C and trimethylsilyl trifluoromethanesulfonate ( 1.84 g, 8.3 mmol) was added dropwise during 5 min. The resulted mixture was stirred for 5 hours at 0 =C. Then ethyl isocyanate (2.25 g, 31.6 mlnol) was added to the mixture. The resulted mixture was stirred for 24 hours at 15 =C and evaporated under reduced pressure. The to residue was dissolved in THF (30 rnL) and triethylamine trihydrofluoride (1.40 g, 8.7 mmol) was added to the solution. The solution was stirred for 2-3 hours (TLC monitoring) at room temperature. Diethyl ether (60 mL) and sat aq sodium bicarbonate solution (50 mL, careful addition!) were added and the resulted two-phase mixture was stirred for 20 min. Then the phases were separated and is the aq phase was washed with diethyl ether. The combined organics were washed with water and brine, dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified on a short silica gel column followed by crystallization from diethyl ether and vacuum desiccation to give 3.24 g (90 %) of [la] as a white solid.
Typical procedure B.
The solution of amide [2a], triethylainine and ethyl isocyanate in dichloromethane was cooled to 0 =C under argon and trimethylsilyl trifluoromethanesulfonate (1.84 g, 8.3 mmol) in dichloromethane (5 mL) was 2s added dropwise. The resulted mixture was stirred for 20 min at 0 -C and for additional 24 h at 15 ~C. Work-up and purification of the final product were carried out as described in the procedure A.
Examples 2-15 H R
O N~NMe~ O N~NMe~
1. TMSOTf Et N
N~ Et.NCO H N
I ~ ~H I ~ H
HN-~ [ 2a ] 2. Desi~ylation RZON I
[ 1a ] R~ = EtNHCO, Rio = H, Cabergoline;
[9] R~=H,Rl°=EtNHCO, ] R~ = R1o = EtNHCO
s Scheme 5 Table 1. Reaction between [2a] and ethyl isocyanate. Effect of solvent, temperature and amounts of trimethylsilyl trifluoromethanesulfonate (TMSOTf) and ethyl isocyanate on reaction yield and selectivity Ex. TMSOTf EtNCO Solvent T, C Yield la/9/lOd no. (eq.) (eq.) (procedure)a(time, of h) la, 2 1.05 1 CHaCl2 (A) 0(5), rt(24)62 99.4:0.3 :0.3 3 1.05 2 CHzCl2 (A) 0(5), rt(24)70 99.0:0.3 :0.7 4 1.05 3-5 CH2C12 (A) 0(5), 90-95 99.7:0:0.3 15(24) 1.05 3-5 CH2C12 (B) 15(24) 88-92" 99.6:0:0.4 6 1.1 3-5 CH2C12 (A) 0(5), rt(24)86" 99.1:0. I
:0.7 7 1.1 3-5 CH2C12 (A) 0(5), 83U 94.0:0.5:5.2 40(24) 8 1.2 3-5 CH2Cl2 (A) 0(5), rt(24)78" 98.2:0.8:1.0 9 I .5 3-5 CH2C12 (A) 0(5), rt(24)69" 96.5:0.5:3.0 2.0 3-5 CH2C12 (A) 0(5), rt(24)64 85.0:1.0:13.7 11 2.5 3-5 CH2Cl2 (A) 0(5), rt(24)56 72.9:1.1:25.3 12 1.1 3 Et20 (A) 0(5), rt(24)65 99.3:0.3:0.4 13 1.1 3 Et20 (B) rt(24) 65 99.1:0.3:0.6 14 1.5 3 Et20 (A) 0(5), rt(24)58 95.5:1.0:3.5 1.1 3-5 Toluene(A) 0(5), rt(24)50 97.7:1.3:1.0 a Procedures A or B described in example 1;
b Crystallized from diethyl ether;
° Purified by short silica gel column;
d Monitored by HPLC of the crude product.
to Examples 16-23 H R
O N~NMe2 O N~NMe2 1. Me3SiY
H''~ N Et3N H'' N
\ H EtNCO I ~ H
i i HN ~ [ ~a ] 2. Desilylation RloN I
[ 1a ] R~ = EtNHCO, Rlo = H, Cabe~goline;
[ 9 ] R~ = H, R1° = EtNHCO, [ 10 ] R~ = R1o = EtNHCO
Scheme 6 Table 2. Reaction between [2a] and ethyl isocyanate with different silylating agents according to method A of Example 1.
Ex. Silylating Solvent T C, (time, Yield Ia/9/10 No. agents (eq.) h) of la, 16 HMDS (>2) CH2C12 0 (5), reflux no reaction (24) 17 ~S (>2) Toluene 0 (5), reflux no reaction (24) 18 TMSCI (>2) CH2Cl2 0 (5), reflux 17 99.0/0/1.0 (24) 19 TMSCl (>2) Toluene 0 (5), reflux 24" 99.0/0/1.0 (24) 20 TMSI (1.05) CH2C12 0 (5), 10 (24)92a 99.6/0/0.4 21 TMSBr (1.2) THF 50 (24) 94a 99.4/0.3/0.3 22 TMSOBs (1.2)THF 50 (24) 83" 98.7/0.4/0.9 23 MTDA (2.0) MeCN reflux (24) 89a 99.7/0/0.3 " Crystallized from diethyl ether s b Purified by short silica gel column Monitored by HPLC of the crude product d Silylation agents: HMDS -1,1,1,3,3,3-hexamethyldisylazane, TMSCI -trimethylsilyl chloride, TMSI - trimethylsilyl iodide, TMSBr - trimethylsilyl bromide, TMSOBs - trimethylsilyl benzenesulfonate, MTDA - methyl ~o trimethylsilyl dimethylketene acetal.
Example 24 1-Phenyl-3-[3-(dimethylamino)propyl]-3-(6-allylergoline-8(3-carbonyl)urea [1b]
O~ NHPh ~H
~ NMe2 ~ NMe2 I. Silylation 2.PhN=C=O
3. Desilylation [2a] [1b]
Scheme 7 According to the method A of Example 1 compound [1b] was obtained using phenyl isocyanate instead of ethyl isocyanate.
1o 1H NMR (CDCl3, ~, ppm) 9.81 (bs, 1H), 8.22 (s, 1H), 7.73 (d, 2H, J=8.0 Hz), 7.31 (t, 2H, J=8.0 Hz), 7.23-7.01 (m, 3H), 6.87 (m, 2H), 5, 92 (m, 1H), 5.23 (d, 1H, J=17.0 Hz), 5.21 (d, 1H, J=9.2 Hz), 3.84 (m, 2H), 3.54 (dd, 1H, J=13.0, 4.6 Hz), 3.32 (m, 2H), 3.15 (d, 1H, J=11.3 Hz), 3.00 (t, 1H, J=5.2 Hz), 2.72 (m, 2H), 2.61 (m, 2H), 2.49 (t, 2H, J=6.6 Hz), 2.14 (s, 3H), 1.83-1.74 (m, 3H).
is
s Y is selected from the group consisting of chloro, bromo, iodo, (haloalkyl)-sulfonyloxy, all~ylsulfonyloxy, arylsulfonyloxy, (trialkylsilyloxy)sulfonyloxy, imidazolyl, N acyl-N-alkylamino, N acyl-N (trialkylsilyl)amino, (trialkylsilyl)-amino, N,N dialkylamino, isopropenyloxy, 1-alkoxy-1-alkenyloxy and trichloroacetoxy radicals;
1o and R2, R3 and R4 are as defined above, to give O-silylated N [ergoline-8~i-carbonyl]urea represented by formula [6]:
,R
~~.SI ~R~
N.RI R8 [6]
is including , tautomers or mixtures thereof, stereoisomers, as well as addition salts thereof, wherein Rl, R~, R3, R4, R6, R~ and Rg are as defined above; following desilylation of the above compounds) to obtain the desired N (ergoline-8~i-carbonyl)urea [I], which can be converted into acid addition salts thereof.
2o The silylating agent may be used in a 0.5 to 10 fold molar amount, preferably from 0.9 to 5 fold molar amount, relative to the amount of the ergoline-8~i-carboxamide [2]. Preferably, silylating agents are selected from -g_ trimethylsilyl trifluoromethanesulfonate, trimethylsilyl methanesulfonate, trimethylsilyl benzenesulfonate, trimethylsilyl chlorosulfonate, trimethylsilyl chloride, bromide or iodide, trimethylsilyl trichloroacetate and trifluoroacetate, 1-(trimethylsilyl)imidazol, I-(trimethylsilyl)-1,2,4-triazole, 1-(trimethylsilyl)-1H-benzotriazole, 1-(trimethylsilyl)-2-pyrrolidinone, N methyl-N (trimethylsilyl)trifluoroacetamide, methyl trimethylsilyl dimethyll~etene acetal, bis(trimethylsilyl)sulfate, N,O-bis(trimethylsilyl)acetamide and bis(trimethylsilyl)trifluoroacetamide.
The silylation reaction may be carried out from -50 °C to the reflux to temperature of the reaction mixture. Preferably, the silylation is carried out from 0° to 50 °C.
Organic or inorganic acids or salts may accelerate the silylation.
Examples of such acids include mineral acids such as sulfuric acid or hydrogen halide. Examples of salts include metal halides, tertiary ammonium halides, is ammonium halides, ammonium sulfate, pyridine or it's derivatives hydrohalides.
However, preferably, organic or inorganic bases accelerate the silylation reaction.
Examples of organic bases are tertiary amines, sterically hindered secondary amines, pyridine or there derivatives, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or mixture thereof. Examples of 2o tertiary amines include I-ethylpiperidine, 1-butylpyrrolidine, diisopropylethylamine, triethylamine, N,N,N,N-tetramethylethylenediamine, 1,4-diazabicyclo[2.2.2]octane or mixture thereof. Examples of sterically hindered secondary amines are diisopropylamine, dicyclohexylamine, 2,2,6,6-tetramethylpiperidine or mixture thereof. Examples of pyridine 25 derivatives axe 4-dimethylaminopyridine (DMAP), 4-(4-methylpiperidino)pyridine and 4-pyrrolidinopyridine or mixture thereof.
The solvent for the silylation reaction may be any suitable aprotic organic solvent provided it does not inhibit the reaction. Examples thereof include aromatic hydrocarbons such as benzene, toluene and xylene, chlorobenzene, 30 o-dichlorobenzene, m-dichlorobenzene and bromobenzene; hydrocarbon halides such as dichloromethane and chloroform; ether solvents such as ether, isopropyl ether, tent-butyl methyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, tetrahydrofuran (THF); ester-type solvents such as ethyl acetate, isopropyl acetate, butyl acetate; or highly polar aprotic organic solvents such as acetonitrile, s N,N dimethylformamide (DMF), N,N dimethylacetamide or 1-methylpyrrolidinone (NMP).
The resultant silylated product may be used in the following step after isolation from the reaction mass, or may be subjected to the subsequent step without isolation.
1o After silylation, the resultant product is reacted with a compound of formula [5], which may be used in a 1 to 10 fold molar amount, preferably 2 to fold molar amount relative to the amount of the ergoline-8~i-carboxamide [2].
The reaction may be carried out at temperature from -50 °C to reflux temperature of the reaction mixture. Preferably, the reaction is carried out at 0 - 50 °C without is isolating silylated ergoline-8(3-carboxamide from the reaction mass.
The reaction of silylated ergoline-8(3-carboxamide with isocyanate may be carried out without solvent, but preferably, the reaction is carried out in any organic aprotic solvent which does not inhibit the reaction. Examples thereof include aromatic hydrocarbons such as benzene, toluene and xylene, 2o chlorobenzene, o-dichlorobenzene, m-dichlorobenzene and bromobenzene;
hydrocarbon halides such as dichloromethane and chloroform; ether solvents such as ether, isopropyl ether, tent-butyl methyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, tetrahydrofuran (THF); ester-type solvents such as ethyl acetate, isopropyl acetate, butyl acetate; or highly polar aprotic organic solvents 2s such as acetonitrile, N,N dimethylformamide (DMF), N,N dimethylacetamide or 1-methylpyrrolidinone (NMP).
Optionally, the reaction of silylated ergoline-8(3-carboxamide with isocyanate may be accelerated by transition metals) salts) and/or coordination compounds) or fluoride-ions. Examples of the said transition metals include 3o copper or zinc. Preferably, the said transition metals) salts) are copper and/or zinc halides. Preferably the said ligands in the coordination compounds) with transition metals) contain phosphorous, nitrogen and/or oxygen atoms. Examples of the ligands include triarylphosphines, pyridine or it's derivatives, tertiary amines, nitrites, amides and ether-type compounds.
The desilylation can be carried out by, for example, using fluoride salts optionally in the presence of phase transfer catalysts. Examples of the said fluoride salts include tetraalkylammonium fluoride, benzyltrialkylammonium fluoride and alkali metal fluoride. Examples of the said phase transfer catalysts include tetraalkylammonium salts, benzyltrialkylammonium salts and crown to ethers.
Cabergoline [la] may be prepared from amide [2a] according to Scheme 3:
R6 Rs_Si -R~
~, NMe2 Y_Si R~ n ~y/'~, NMe2 i8 R
[3]
[2a] [4a]
~, EtNCO
R~
O NHEt RS Si0 NEt n ~.T~NMe2 n rr~NMe2 Desilylation [ 6a ]
Cabergoline ( la ]
Scheme 3 The invention will be further described in more detail with the following non-limiting examples.
Example 1 Cabergoline [Ia]
O \ / NHEt ~'H
~ NMe2 ~ NMe2 1. TMSOTf/Et3N
EtN=C=O
2. Desilylation [ ~a ] ~u~
Cabergoline [ Ia ]
to Scheme 4 Typical procedure A.
A tree-necked round-bottom flask fitted with a reflux condenser (optional), thermometer and septum was evacuated, dried and flushed with dry nitrogen or argon. Solution of amide [2a] (3.00 g, 7.9 mmol) and triethylamine s (1.11 g, 11.0 mmol) in dichloromethane (30 mL) was cooled to 0 =C and trimethylsilyl trifluoromethanesulfonate ( 1.84 g, 8.3 mmol) was added dropwise during 5 min. The resulted mixture was stirred for 5 hours at 0 =C. Then ethyl isocyanate (2.25 g, 31.6 mlnol) was added to the mixture. The resulted mixture was stirred for 24 hours at 15 =C and evaporated under reduced pressure. The to residue was dissolved in THF (30 rnL) and triethylamine trihydrofluoride (1.40 g, 8.7 mmol) was added to the solution. The solution was stirred for 2-3 hours (TLC monitoring) at room temperature. Diethyl ether (60 mL) and sat aq sodium bicarbonate solution (50 mL, careful addition!) were added and the resulted two-phase mixture was stirred for 20 min. Then the phases were separated and is the aq phase was washed with diethyl ether. The combined organics were washed with water and brine, dried over sodium sulfate, filtered and evaporated under reduced pressure. The residue was purified on a short silica gel column followed by crystallization from diethyl ether and vacuum desiccation to give 3.24 g (90 %) of [la] as a white solid.
Typical procedure B.
The solution of amide [2a], triethylainine and ethyl isocyanate in dichloromethane was cooled to 0 =C under argon and trimethylsilyl trifluoromethanesulfonate (1.84 g, 8.3 mmol) in dichloromethane (5 mL) was 2s added dropwise. The resulted mixture was stirred for 20 min at 0 -C and for additional 24 h at 15 ~C. Work-up and purification of the final product were carried out as described in the procedure A.
Examples 2-15 H R
O N~NMe~ O N~NMe~
1. TMSOTf Et N
N~ Et.NCO H N
I ~ ~H I ~ H
HN-~ [ 2a ] 2. Desi~ylation RZON I
[ 1a ] R~ = EtNHCO, Rio = H, Cabergoline;
[9] R~=H,Rl°=EtNHCO, ] R~ = R1o = EtNHCO
s Scheme 5 Table 1. Reaction between [2a] and ethyl isocyanate. Effect of solvent, temperature and amounts of trimethylsilyl trifluoromethanesulfonate (TMSOTf) and ethyl isocyanate on reaction yield and selectivity Ex. TMSOTf EtNCO Solvent T, C Yield la/9/lOd no. (eq.) (eq.) (procedure)a(time, of h) la, 2 1.05 1 CHaCl2 (A) 0(5), rt(24)62 99.4:0.3 :0.3 3 1.05 2 CHzCl2 (A) 0(5), rt(24)70 99.0:0.3 :0.7 4 1.05 3-5 CH2C12 (A) 0(5), 90-95 99.7:0:0.3 15(24) 1.05 3-5 CH2C12 (B) 15(24) 88-92" 99.6:0:0.4 6 1.1 3-5 CH2C12 (A) 0(5), rt(24)86" 99.1:0. I
:0.7 7 1.1 3-5 CH2C12 (A) 0(5), 83U 94.0:0.5:5.2 40(24) 8 1.2 3-5 CH2Cl2 (A) 0(5), rt(24)78" 98.2:0.8:1.0 9 I .5 3-5 CH2C12 (A) 0(5), rt(24)69" 96.5:0.5:3.0 2.0 3-5 CH2C12 (A) 0(5), rt(24)64 85.0:1.0:13.7 11 2.5 3-5 CH2Cl2 (A) 0(5), rt(24)56 72.9:1.1:25.3 12 1.1 3 Et20 (A) 0(5), rt(24)65 99.3:0.3:0.4 13 1.1 3 Et20 (B) rt(24) 65 99.1:0.3:0.6 14 1.5 3 Et20 (A) 0(5), rt(24)58 95.5:1.0:3.5 1.1 3-5 Toluene(A) 0(5), rt(24)50 97.7:1.3:1.0 a Procedures A or B described in example 1;
b Crystallized from diethyl ether;
° Purified by short silica gel column;
d Monitored by HPLC of the crude product.
to Examples 16-23 H R
O N~NMe2 O N~NMe2 1. Me3SiY
H''~ N Et3N H'' N
\ H EtNCO I ~ H
i i HN ~ [ ~a ] 2. Desilylation RloN I
[ 1a ] R~ = EtNHCO, Rlo = H, Cabe~goline;
[ 9 ] R~ = H, R1° = EtNHCO, [ 10 ] R~ = R1o = EtNHCO
Scheme 6 Table 2. Reaction between [2a] and ethyl isocyanate with different silylating agents according to method A of Example 1.
Ex. Silylating Solvent T C, (time, Yield Ia/9/10 No. agents (eq.) h) of la, 16 HMDS (>2) CH2C12 0 (5), reflux no reaction (24) 17 ~S (>2) Toluene 0 (5), reflux no reaction (24) 18 TMSCI (>2) CH2Cl2 0 (5), reflux 17 99.0/0/1.0 (24) 19 TMSCl (>2) Toluene 0 (5), reflux 24" 99.0/0/1.0 (24) 20 TMSI (1.05) CH2C12 0 (5), 10 (24)92a 99.6/0/0.4 21 TMSBr (1.2) THF 50 (24) 94a 99.4/0.3/0.3 22 TMSOBs (1.2)THF 50 (24) 83" 98.7/0.4/0.9 23 MTDA (2.0) MeCN reflux (24) 89a 99.7/0/0.3 " Crystallized from diethyl ether s b Purified by short silica gel column Monitored by HPLC of the crude product d Silylation agents: HMDS -1,1,1,3,3,3-hexamethyldisylazane, TMSCI -trimethylsilyl chloride, TMSI - trimethylsilyl iodide, TMSBr - trimethylsilyl bromide, TMSOBs - trimethylsilyl benzenesulfonate, MTDA - methyl ~o trimethylsilyl dimethylketene acetal.
Example 24 1-Phenyl-3-[3-(dimethylamino)propyl]-3-(6-allylergoline-8(3-carbonyl)urea [1b]
O~ NHPh ~H
~ NMe2 ~ NMe2 I. Silylation 2.PhN=C=O
3. Desilylation [2a] [1b]
Scheme 7 According to the method A of Example 1 compound [1b] was obtained using phenyl isocyanate instead of ethyl isocyanate.
1o 1H NMR (CDCl3, ~, ppm) 9.81 (bs, 1H), 8.22 (s, 1H), 7.73 (d, 2H, J=8.0 Hz), 7.31 (t, 2H, J=8.0 Hz), 7.23-7.01 (m, 3H), 6.87 (m, 2H), 5, 92 (m, 1H), 5.23 (d, 1H, J=17.0 Hz), 5.21 (d, 1H, J=9.2 Hz), 3.84 (m, 2H), 3.54 (dd, 1H, J=13.0, 4.6 Hz), 3.32 (m, 2H), 3.15 (d, 1H, J=11.3 Hz), 3.00 (t, 1H, J=5.2 Hz), 2.72 (m, 2H), 2.61 (m, 2H), 2.49 (t, 2H, J=6.6 Hz), 2.14 (s, 3H), 1.83-1.74 (m, 3H).
is
Claims (20)
1. A process for the preparation of a compound of the formula [I]:
including stereoisomers as well as acid addition salts thereof, wherein R1 is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl, R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; which process comprises silylating with a silylation agent a compound represented by the formula [2]:
including stereoisomers as well as metal or ammonium salts or acid addition salts thereof, wherein R2, R3 and R4 are as defined above, and reacting the resultant product with a compound represented by the formula [5]:
wherein R1 is as defined above, followed by desilylation.
including stereoisomers as well as acid addition salts thereof, wherein R1 is selected from alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, and dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)nNMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl, R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; which process comprises silylating with a silylation agent a compound represented by the formula [2]:
including stereoisomers as well as metal or ammonium salts or acid addition salts thereof, wherein R2, R3 and R4 are as defined above, and reacting the resultant product with a compound represented by the formula [5]:
wherein R1 is as defined above, followed by desilylation.
2. A process according to claim 1 wherein said silylation is carried out by contacting a compound [2], stereoisomers as well as metal or ammonium salts or acid addition salts thereof with a silylating agent represented by the formula [3]
wherein R6, R7 and R8 may be the same or different and are selected from the group consisting of alkyl having from 1 to 6 carbon atoms, aryl and aralkyl radicals; Y is selected from the group consisting of chloro, bromo, iodo, (haloalkyl)sulfonyloxy, alkylsulfonyloxy, arylsulfonyloxy, (trialkylsilyloxy)-sulfonyloxy, imidazolyl, N acyl-N alkylamino, N acyl-N (trialkylsilyl)amino, (trialkylsilyl)amino, N,N dialkylamino, isopropenyloxy, 1-alkoxy-1-propenyloxy and trichloroacetoxy radicals; to give intermediate compound represented by the formula [4]:
including tautomers or mixtures thereof, stereoisomers, as weu as acid addition salts thereof wherein R2, R3, R4, R6, R7 and R8 are as defined above, which react with compound [5] to give a compound represented by the formula [6]
including tautomers or mixtures thereof, stereoisomers, as well as acid addition salts thereof, wherein R1, R2, R3, R4, R6, R7 and R8 are as defined above; following desilylation thereof to obtain the desired compound [I] or acid addition salts thereof.
wherein R6, R7 and R8 may be the same or different and are selected from the group consisting of alkyl having from 1 to 6 carbon atoms, aryl and aralkyl radicals; Y is selected from the group consisting of chloro, bromo, iodo, (haloalkyl)sulfonyloxy, alkylsulfonyloxy, arylsulfonyloxy, (trialkylsilyloxy)-sulfonyloxy, imidazolyl, N acyl-N alkylamino, N acyl-N (trialkylsilyl)amino, (trialkylsilyl)amino, N,N dialkylamino, isopropenyloxy, 1-alkoxy-1-propenyloxy and trichloroacetoxy radicals; to give intermediate compound represented by the formula [4]:
including tautomers or mixtures thereof, stereoisomers, as weu as acid addition salts thereof wherein R2, R3, R4, R6, R7 and R8 are as defined above, which react with compound [5] to give a compound represented by the formula [6]
including tautomers or mixtures thereof, stereoisomers, as well as acid addition salts thereof, wherein R1, R2, R3, R4, R6, R7 and R8 are as defined above; following desilylation thereof to obtain the desired compound [I] or acid addition salts thereof.
3. A process according to claim 1 wherein R1 is ethyl, R2 is dimethylaminopropyl, R3 is allyl group, R4 is hydrogen, R6, R7 and R8 are methyl groups.
4. Compounds represented by the formula [4]:
including stereoisomers as well as acid addition salts thereof, wherein R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)n NMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl, R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; and R6, R7 and R8 may be the same or different and are selected from the group consisting of alkyl having from 1 to 4 carbon atoms, aryl and aralkyl radicals.
including stereoisomers as well as acid addition salts thereof, wherein R2 is selected from hydrogen, alkyl having from 1 to 4 carbon atoms, cyclohexyl, phenyl, dimethylamino alkyl group -(CH2)n NMe2 in which n is an integer, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl or thiadiazolyl, R3 represents a hydrocarbon group having from 1 to 4 carbon atoms, and R4 is selected from hydrogen, halogen, methylthio and phenylthio group; and R6, R7 and R8 may be the same or different and are selected from the group consisting of alkyl having from 1 to 4 carbon atoms, aryl and aralkyl radicals.
5. A process according to claim 1 which is carried out in an aprotic organic solvent.
6. A process according to claim 5 wherein the solvent is an aromatic hydrocarbon, a hydrocarbon halide, an ether-type, an ester-type or a highly polar aprotic organic solvent.
7. A process according to claim 6 wherein the solvent is dichloromethane, chloroform, toluene, ether, isopropyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, tetrahydrofurane (THF), ethyl acetate, isopropyl acetate, butyl acetate, acetonitrile, N,N dimethylformamide (DMF), N,N dimethylacetamide or 1-methylpyrrolidinone (NMP).
8. A process according to claim 1 wherein the silylating agent is selected from trimethylsilyl trifluoromethanesulfonate, trimethylsilyl methanesulfonate, trimethylsilyl benzenesulfonate, trimethylsilyl chlorosulfonate, trimethylsilyl chloride, bromide, iodide, trichloroacetate or trifluoroacetate, -(trimethylsilyl)imidazol, 1-(trimethylsilyl)-1,2,4-triazole, -(trimethylsilyl)-1H-benzotriazole, 1-(trimethylsilyl)-2-pyrrolidinone, N-methyl-N (trimethylsilyl)trifluoroacetamide, methyl trimethylsilyl dimethylketene acetal, bis(trimethylsilyl)sulfate, N, O-bis(trimethylsilyl)acetamide end bis(trimethylsilyl)trifluoroacetamide.
9. A process according to claim 1 wherein 1 to 5-fold molar amount of silylating agent relative to compound [2] is used for silylating of compound [2].
10. A process according to claim 2 wherein 1 to 5-fold molar amount of silylating agent [3] relative to compound [2] is used for silylating of compound [2].
11. A process according to claim 1 wherein said silylation is carried out in the presence of organic or inorganic bases, salts or acids.
12. A process according to claim 2 wherein said silylation is carried out in the presence of organic or inorganic bases, salts or acids.
13. A process according to claim 11 wherein said organic bases are tertiary amines, sterically hindered secondary amines, pyridine or there derivatives,.
1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or mixture thereof.
1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or mixture thereof.
14. A process according to claim 13 wherein said tertiary amines are selected from 1-ethylpiperidine, 1-butylpyrrolidine, diisopropylethylamine, triethylamine, N,N,N',N'-tetramethylethylenediamine, 1,4-diazabicyclo[2.2.2]octane or mixture thereof.
15. A process according to claim 13 wherein said sterically hindered secondary amines are selected from diisopropylamine, dicyclohexylamine, 2,2,6,6-tetramethylpiperidine or mixture thereof.
16. A process according to claim 13 wherein said pyridine derivatives are 4-dimethylaminopyridine (DMAP), 4-(4-methylpiperidino)pyridine and 4-pyrrolidinopyridine or mixture thereof.
17. A process according to claim 11 wherein said salts are selected from metal halides, tertiary ammonium halides, ammonium halides, ammonium sulfate and pyridine or it's derivatives hydrohalides or mixture thereof.
18. A process according to claim 11 wherein said acids are selected from p-toluenesulfonic acid, methanesulfonic acid, sulfuric acid and hydrogen halides.
19. A process according to claim 1 wherein the compound [5] is used in a 1-to 5-fold molar amount relative to the compound [2].
20. A process according to claim 2 wherein the compound [5] is used in a 1-to 5-fold molar amount relative to the compound [2].
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2001/000344 WO2002085902A1 (en) | 2001-04-16 | 2001-04-16 | Process and intermediates for production of cabergoline and related compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2412861A1 true CA2412861A1 (en) | 2002-10-31 |
Family
ID=11043042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002412861A Abandoned CA2412861A1 (en) | 2001-04-16 | 2001-04-16 | Process and intermediates for production of cabergoline and related compounds |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1379526A1 (en) |
| JP (1) | JP2004525187A (en) |
| CA (1) | CA2412861A1 (en) |
| HU (1) | HUP0303557A2 (en) |
| WO (1) | WO2002085902A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939665B2 (en) | 2007-05-04 | 2011-05-10 | Apotex Pharmachem Inc. | Efficient process for the preparation of cabergoline and its intermediates |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2450645T3 (en) | 2003-04-11 | 2014-03-25 | Ipsen Pharma | Chimeric somatostatin-dopamine analogs |
| HUP0400517A3 (en) * | 2004-03-04 | 2006-05-29 | Richter Gedeon Vegyeszet | Process for producing cabergoline |
| FR2877945A1 (en) * | 2004-11-18 | 2006-05-19 | Archemis Sa | PROCESS FOR THE PREPARATION OF CABERGOLIN |
| WO2006097345A1 (en) | 2005-03-17 | 2006-09-21 | Synthon Argentina S.A. | Improved process for making cabergoline |
| GB0602557D0 (en) * | 2006-02-08 | 2006-03-22 | Resolution Chemicals Ltd | Production of cabergoline and novel polymorphic form thereof |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| TWI523863B (en) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | Somatostatin-dopamine chimeric analogs |
| CN104768565B (en) | 2012-11-01 | 2017-04-26 | 益普生制药股份有限公司 | Somatostatin analogs and dimers thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
-
2001
- 2001-04-16 EP EP01923942A patent/EP1379526A1/en not_active Withdrawn
- 2001-04-16 WO PCT/IL2001/000344 patent/WO2002085902A1/en not_active Application Discontinuation
- 2001-04-16 HU HU0303557A patent/HUP0303557A2/en unknown
- 2001-04-16 JP JP2002583429A patent/JP2004525187A/en active Pending
- 2001-04-16 CA CA002412861A patent/CA2412861A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939665B2 (en) | 2007-05-04 | 2011-05-10 | Apotex Pharmachem Inc. | Efficient process for the preparation of cabergoline and its intermediates |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002085902A1 (en) | 2002-10-31 |
| JP2004525187A (en) | 2004-08-19 |
| HUP0303557A2 (en) | 2004-03-01 |
| EP1379526A1 (en) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4731503B2 (en) | Method for sulfinylation of heterocyclic compounds | |
| CA2412861A1 (en) | Process and intermediates for production of cabergoline and related compounds | |
| EP0126968B1 (en) | Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing same | |
| Sugimoto et al. | Activation of dithiocarbamate by 2-halothiazolium salts | |
| NO317258B1 (en) | Process for the preparation of a protected 4-aminomethyl-pyrrolidin-3-one | |
| US6696568B2 (en) | Process and intermediates for production of cabergoline and related compounds | |
| EP1720869B1 (en) | Process for the preparation of cabergoline | |
| WO2003072552A1 (en) | Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide | |
| ZA200407821B (en) | Compounds useful in preparing camptothecin derivatives. | |
| AU2001250622A1 (en) | Process and intermediates for production of cabergoline and related compounds | |
| MXPA02000316A (en) | Benzofurane derivatives. | |
| CZ20024100A3 (en) | Process and intermediates for preparing cabergoline and related compounds | |
| IL134975A (en) | Process for producing cabergoline and related compounds and novel intermediates therefor | |
| JP3448635B2 (en) | Sulfenamide compound and method for producing the same | |
| AU2002336606B2 (en) | Synthesis of 2-cyanoziridine-1-carboxamide | |
| ZA200402070B (en) | Synthesis of 4-(piperidyl)(2-pyridy)methanone-(E)-O-methyloxime and its salts. | |
| NO179903B (en) | Process for the preparation of a haloacetamide derivative and a pyrrolidinylacetamide derivative | |
| AU2019268945B2 (en) | Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof | |
| JP7096078B2 (en) | A method for producing a semicarbazide compound and a method for producing a triazolidinedione compound. | |
| AU635024B2 (en) | Novel compounds | |
| GB2102800A (en) | Pyrimidines | |
| JPH06228149A (en) | Novel pentacyclic heterocyclic compound, production intermediate and their production | |
| PL189248B1 (en) | Method of obtaining 1-(p-methoxybenzooyl)-2-pyrolydone | |
| JPH0446175A (en) | Production of 5-hydroxy-3,4-methylenedioxybenzoic acid derivative | |
| Qing‐Min et al. | New reactions of N‐T‐butyl‐N‐benzoylhydrazine with triphosgene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |